Jeswani H, Jeswani AK. Comment on Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial. J Gastroenterol Hepatol 2026 Aug 4. doi: 10.1111/jgh.70655.
PMID: 42552515